Coronary Microvascular Disease

  • 1st Revision: Shagun Dhaliwal
  • 2nd Revision: Manjutha Subbiah
  • 3rd Revision: Kaamya Mehta[Linkedin]


What is Coronary Microvascular Disease?

Coronary microvascular disease (CMVD) is a group of disorders. It affects the tiny arteries feeding the heart (coronary vasculature), making them lose the capacity to accommodate blood flow (contraction and dilation to meet the oxygen and nutrient needs of the cardiovascular system). It is often signaled by chest pain (usually leaving an electrocardiographic signature) when the arteries narrow too much. Besides frequent spasms, there is a poor response to neurotransmitters (like acetylcholine) and other neurochemicals that open up the blood vessels.1

In normal physiological conditions, coronary blood supply (laden with oxygen and nutrients) matches circulatory demand. The interactions of metabolic, hormonal, neuromuscular, and neurochemical factors maintain this balance in the endothelium and ensure that optimal tone of the blood vessels is achieved.2

Other names for CMVD are cardiac syndrome X, nonobstructive coronary heart disease, and microvascular angina.2 It has been estimated that the condition affects about 30% of patients with angina. 

Signs and Symptoms

The condition’s clinical symptoms are usually shortness of breath during exertion, angina (chest pain), lethargy, and restlessness. However, many cases may pass as asymptomatic.3

Risk Factors

There are many factors that increase the risk of developing CMVD.1 Some include: 

  • Being assigned female at birth (AFAB) (research findings those AFAB are three times more likely though this has not been conclusively proven)
  • Menopause
  • Age
  • Poor diet (especially those loaded with bad cholesterol)
  • Hypertension 
  • History of smoking
  • Obesity  
  • Hereditary factors (family history)
  • Lipid disorders (dyslipidemia)
  • Diabetes mellitus

In turn, CMVD increases the risk of heart failure, myocardial infarction (heart attacks), nonobstructive coronary artery disease, and atherosclerosis of larger blood vessels.


The choice of diagnostic method boils down to the expertise of the investigator, cost, availability, and even patient preference.3 Each diagnostic method has its pros and cons; the consulting physician can recommend more than one of these tests.

Broadly speaking, they include the following methods:  

Coronary angiography

X-ray coronary angiography is often used as a confirmatory diagnosis, as it is capable of differentiating CMVD from epicardial coronary artery disease.4 It is an invasive method involving physical contact with tissue to be investigated that involves intravenous insertion of a probe (catheter) or a contrasting agent, which is the mainstay for diagnosis of CMVD.

Stress test

Exercise stress testing (with or without imaging) is another method for identifying CMVD in patients. The patient is typically placed on a treadmill and cardiovascular biomarkers (like heart rate and blood pressure) are monitored in response to patient activity. A positive result suggests obstructive coronary artery disease. However, the sensitivity and specificity of the test are poor.3 This limits its role in the modern-day diagnosis of CMVD.

Coronary magnetic resonance (CMR) imaging

CMR is an example of radiographic (imaging) procedures that exploit electromagnetic radiation to observe and assess blood flow through the coronary vascular space. They are important for noninvasive diagnosis of the condition. Besides CMR imaging, other noninvasive imaging tests are PET (positron emission tomography) scans and CT (computed tomography) scans.4

Duke Activity Status Index (DASI)

DASI comes in the form of a 12-point questionnaire that considers daily routine vis-à-vis cardiovascular fitness. It serves as a self-assessment tool useful in quickly evaluating the level of risk and the functional capacity of patients with CMVD.5 It is cost-effective and can easily be administered. 


Treating the condition involves interrupting the pathways that control inflammation, abnormal contraction of coronary blood microvessels (arteries) and blood clotting (thromboses). These medications are found to be beneficial either for symptom control or for modifying the course of the disease.1,3 They include: 

  • Low-dose aspirin: It is a common blood thinner that blocks the clumping together (aggregation) of blood platelets. Higher therapeutic doses of the medication have an added advantage of pain relief. 
  • Statins: These interrupt the inflammation-driven deposition of lipids (e.g. low-density cholesterol) within the microvessels by interfering with production. 
  • Antianginal medications: They directly widen (dilate) the constricted blood vessels through different mechanisms ultimately improving coronary blood flow (e.g. calcium channel blockers, beta-blockers, nitrates, and ranolazine).   
  • Angiotensin-converting enzyme inhibitors (e.g. quinapril): They target the reduction of cardiovascular inflammation and block the effects of the enzyme (angiotensin II) which constricts the blood vessel.

The medications, provided they are not interacting negatively, can be combined to achieve better results. 


It is important to note that controlling blood pressure, lipids, and sugar levels (by medication or lifestyle adjustment) can go a long way in reducing symptoms. Non-drug measures of intervention include proper nutrition (balanced diet), regular exercise, avoidance of smoking, and stress and weight reduction. While such measures seem simple, they can make a huge difference in terms of preventing CMVD.   

Contacting your doctor

Coronary microvascular disease is a complex condition whose management requires the attention of a specialist. The management plan stretches from diagnosis to actual treatment and regular monitoring. It is best practice to alert your GP once you experience symptoms like chest pain or unusual breathlessness on exertion or even at rest. Medications for managing coronary microvascular disease must be taken strictly based on prescription, as they are regarded as highly potent.   


Coronary microvascular disease is a complex condition. It reflects the mismatch between coronary blood supply and the demand for oxygen and nutrients required for cardiovascular health. It can be detected by clinical presentations which can be typical, atypical, or asymptomatic. However, several invasive and noninvasive diagnostic measures are in place to guide treatment decisions. Such measures tend to differ in terms of cost and accuracy.   

Ultimately, careful consideration of the risk factors and preventive measures are important for understanding and managing the condition, given that CMVD is managed by an experienced cardiovascular specialist. Adjusting the modifiable risk factors like diet and smoke cessation, along with pharmacotherapy helps reduce symptoms, improving overall treatment outcomes. 


  1. Thakker RA, Rodriguez Lozano J, Rodriguez Lozano P, Motiwala A, Rangasetty U, Khalife W, et al. Coronary Microvascular Disease. Cardiol Ther [Internet]. 2022 [cited 2022 Jul 23]; 11(1):23–31. Available from:
  2. Sinha A, Rahman H, Perera D. Coronary microvascular disease: current concepts of pathophysiology, diagnosis and management. Cardiovascular Endocrinology & Metabolism [Internet]. 2020 [cited 2022 Jul 23]; 10(1):22–30. Available from:
  3. Taqueti VR, Di Carli MF. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options. Journal of the American College of Cardiology [Internet]. 2018 [cited 2022 Jul 24]; 72(21):2625–41. Available from:
  4. Markousis‐Mavrogenis G, Bacopoulou F, Mavragani C, Voulgari P, Kolovou G, Kitas GD, et al. Coronary microvascular disease: The “Meeting Point” of Cardiology, Rheumatology and Endocrinology. Eur J Clin Investigation [Internet]. 2022 [cited 2022 Jul 24]; 52(5). Available from:
  5. George MJ, Kasbekar SA, Bhagawati D, Hall M, Buscombe JR. The value of the Duke Activity Status Index (DASI) in predicting ischaemia in myocardial perfusion scintigraphy - a prospective study. Nucl Med Rev Cent East Eur. 2010; 13(2):59–63.
  6. Coronary Microvascular Disease (MVD). [Internet]. [cited 2022 Jul 24]. Available from:
This content is purely informational and isn’t medical guidance. It shouldn’t replace professional medical counsel. Always consult your physician regarding treatment risks and benefits. See our editorial standards for more details.

Get our health newsletter

Get daily health and wellness advice from our medical team.
Your privacy is important to us. Any information you provide to this website may be placed by us on our servers. If you do not agree do not provide the information.

Ezekwesiri Nwanosike

Master's degree - Drug Discovery and Business Strategy, The University of Huddersfield
I am a business-minded Pharmacist who specializes in leveraging clinical data to improve patient wellbeing. My passion is ensuring that quality, safe and effective health information/products are within the reach of everyone.

Leave a Reply

Your email address will not be published. Required fields are marked * presents all health information in line with our terms and conditions. It is essential to understand that the medical information available on our platform is not intended to substitute the relationship between a patient and their physician or doctor, as well as any medical guidance they offer. Always consult with a healthcare professional before making any decisions based on the information found on our website.
Klarity is a citizen-centric health data management platform that enables citizens to securely access, control and share their own health data. Klarity Health Library aims to provide clear and evidence-based health and wellness related informative articles. 
Klarity / Managed Self Ltd
Alum House
5 Alum Chine Road
Westbourne Bournemouth BH4 8DT
VAT Number: 362 5758 74
Company Number: 10696687

Phone Number:

 +44 20 3239 9818